In a landmark regulatory shift, the European Commission has granted approval for AbbVie’s Maviret (glecaprevir/pibrentasvir)—marketed as Mavyret in the United States—to be used for both acute and chronic hepatitis C virus (HCV) infections. This decision marks a significant departure from the traditional "wait-and-see" clinical approach, effectively removing a major barrier to the immediate treatment of patients newly diagnosed with the virus. By eliminating the requirement to confirm chronicity before prescribing therapy, health authorities are signaling a fundamental shift in how the medical community approaches infectious disease management.
Main Facts: A Paradigm Shift in HCV Management
For years, clinical practice was shackled by the necessity of documenting a six-month infection period to confirm a "chronic" status before insurers would authorize life-saving direct-acting antivirals (DAAs). This bureaucratic hurdle often resulted in patients waiting months for treatment, during which time they remained at risk of liver damage and continued to be potential vectors for transmission.
Maviret, a potent, once-daily, fixed-dose combination therapy, works by deploying two mechanisms: glecaprevir, which inhibits the HCV NS3/4A protease (an enzyme vital for viral replication), and pibrentasvir, which targets the NS5A protein (essential for RNA replication and virion assembly). The expanded approval confirms that the therapy is equally effective in the acute phase of the infection as it is in the chronic stage.
This regulatory evolution is designed to align clinical practice with the modern understanding of HCV as a curable, manageable condition. By allowing physicians to treat "the minute you diagnose someone," the new label simplifies the administrative burden and empowers clinicians to prioritize public health outcomes over rigid diagnostic criteria.
Chronology: From Experimental Waiting to Immediate Intervention
The history of HCV treatment is characterized by a long, arduous journey from toxic, low-efficacy regimens to the highly efficient, well-tolerated therapies available today.
The Era of Interferon
Before the mid-2010s, HCV treatment was an ordeal. Patients were subjected to long courses of interferon injections, which carried significant side effects, including severe fatigue, depression, and flu-like symptoms. Because the risk-benefit ratio was unfavorable for early-stage or acute patients, physicians historically adopted a "wait-and-see" approach. They hoped for spontaneous clearance of the virus—a phenomenon observed in roughly 26% of cases—before subjecting patients to the rigors of interferon.
The Emergence of DAAs
The introduction of direct-acting antivirals in the mid-2010s revolutionized hepatology. Suddenly, cure rates spiked into the high 90s, and side effects were drastically reduced. However, clinical habits proved difficult to break. Despite clinical guidance in 2020 suggesting prompt treatment for acute cases, the lack of an official "acute" indication on product labels meant that many health systems continued to mandate proof of chronic infection to satisfy insurance reimbursement criteria.
The Modern Mandate
The European Commission’s 2026 approval serves as the final nail in the coffin for the wait-and-see era. With the expanded label, the medical consensus has shifted: waiting for an infection to become "chronic" is no longer medically defensible, nor is it economically sound when considering the broader societal costs of ongoing transmission.
Supporting Data: The Power of Clinical Efficacy
The regulatory expansion for Maviret is underpinned by robust clinical evidence, most notably the Phase 3 M20-350 trial. This study was specifically designed to evaluate the efficacy and safety of an eight-week regimen of glecaprevir/pibrentasvir in patients with acute HCV.
The results were compelling: 96.2% of patients achieved a sustained virologic response (SVR) 12 weeks after completing the treatment. SVR is the gold standard for measuring a cure in hepatitis C, representing the point at which the virus is no longer detectable in the blood. This success rate demonstrates that the standard eight-to-16-week regimen is not only effective for chronic patients but is perfectly optimized for those caught early in the infection cycle.
Furthermore, the simplicity of the once-daily regimen—a hallmark of Maviret—increases patient adherence. In the context of acute infection, where patients may be transient or less connected to specialized care, a shorter, highly effective treatment course is a critical tool for public health officials aiming to break the chain of transmission.
Official Responses: The View from AbbVie
Mudra Kapoor, Vice President of Neuroscience, Eyecare, Specialty, and VIO Medical Affairs + Health Impact at AbbVie, emphasizes that the regulatory change is as much about logistics as it is about medicine.
"We no longer have to go through additional steps to check for chronicity or worry about how far back they got the infection," Kapoor said in an interview. She notes that while the medical community has recognized the need for early intervention for years, the "ecosystem" of healthcare delivery—insurance companies, national health services, and clinical protocols—was lagging behind the science.
Kapoor argues that the wait-and-see approach is now a moral and clinical failure. "When you look at the benefit-risk equation today, it would almost be a disservice to patients not to treat them," she stated. Beyond individual health, she highlights the "socioeconomic benefit" of treating patients immediately. By curing an individual early, the healthcare system prevents the development of advanced liver disease (cirrhosis or hepatocellular carcinoma) and eliminates the possibility that the patient will transmit the virus to others, effectively curbing the epidemic at the source.
Implications for Global Elimination Goals
The World Health Organization (WHO) has set ambitious targets for the elimination of viral hepatitis by 2030. To reach these, countries must move beyond treating only the sickest patients. They must find the undiagnosed and treat them immediately.
The Lithuania Model
Lithuania serves as a case study for what can be achieved when political will meets pharmaceutical innovation. By implementing a national screening program that incentivized general practitioners to conduct antibody testing, the country saw a tripling of treated patients. However, the Lithuanian experience also highlights that a drug alone is not a panacea. Researchers found that despite massive gains, the country still struggled to meet WHO targets because of persistent restrictions on who qualifies for treatment based on their fibrosis stage.
The Access Gap
While AbbVie has made strides in expanding access, including licensing agreements with the Medicines Patent Pool that allow generic versions of the drug in 99 low- and middle-income countries, the road to total elimination remains bumpy. Critics, including organizations like Médecins Sans Frontières, have argued that despite these agreements, the medication remains financially or logistically inaccessible to many of the most vulnerable populations.
Kapoor acknowledges these challenges, stating, "It takes more than AbbVie to meet these goals. We need policymakers to take action, we need payers to take action, and we need everyone to actually want to eliminate HCV."
The Road Ahead: A New Standard of Care
The approval of Maviret for acute HCV is a milestone that necessitates a total overhaul of standard operating procedures in clinics and hospitals. The goal, as defined by AbbVie and public health advocates, is a "test-and-treat" model. In this future, a positive HCV test result is immediately followed by the initiation of therapy, without the need for additional confirmatory testing, liver biopsies, or waiting periods.
However, moving the needle from "possible" to "achieved" requires a synchronized effort:
- Clinical Education: Physicians must be retrained to discard the obsolete notion that they must wait for a six-month window.
- Policy Reform: Payers and government health departments must update their reimbursement formularies to mirror the new, expanded indication.
- Infrastructure: Increased funding for screening programs is required to find the "hidden" patients who are currently undiagnosed.
As the global medical community looks toward the 2030 deadline, the tools to eradicate hepatitis C are clearly at hand. With the regulatory hurdles removed for one of the most effective treatments in the market, the responsibility now shifts to the broader healthcare ecosystem. The "wait-and-see" era is officially over; the "test-and-treat" era must now begin in earnest.
"There are a couple of other bright spots like that around the globe, which gives us confidence that if we all work together across the whole ecosystem, we can get there," Kapoor concluded. "That future is possible, and AbbVie is completely committed to it."
About the Author
